Cryoglobulinemic disease

ONCOLOGY (United States)

Volumn 27, Issue 11, 2013, Pages

  Retamozo, Soledad ^a   Brito Zerón, Pilar ^a   Bosch, Xavier ^a   Stone, John H ^a   Ramos Casals, Manuel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AZATHIOPRINE; BOCEPREVIR; BORTEZOMIB; CD81 ANTIGEN; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB; TELAPREVIR;

CLINICAL FEATURE; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; CYTOPENIA; DISEASE ASSOCIATION; GENERAL CONDITION DETERIORATION; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; HYPERTRANSAMINASEMIA; HYPERVISCOSITY SYNDROME; INFECTION; MONOCLONAL CRYOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; VIREMIA;

EID: 84888328877     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012; 379: 348-60.
2. Saadoun D, Landau DA, Calabrese LH, et al. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford). 2007; 46: 1234-42.
3. Sargur R, White P, Egner W. Cryoglobulin evaluation: best practice? Ann Clin Biochem. 2010; 47: 8-16.
4. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008; 3: 25.
5. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974; 57: 775-88.
6. Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013; 92: 61-8.
7. Payet J, Livartowski J, Kavian N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013; 54: 767-77.
8. Wang Y, Lomakin A, Hideshima T, et al. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci USA. 2012; 109: 13359-61.
9. Bakker AJ, Slomp J, de Vries T, et al. Adequate sampling in cryoglobulinaemia: recommended warmly. Clin Chem Lab Med. 2003; 41: 85-9.
10. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2012; 119: 2205-8.
11. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009; 114: 2375-85.
12. Ramos-Casals M, Trejo O, García-Carrasco M, et al. Mixed cryoglobulinemia: new concepts. Lupus. 2000; 9: 83-91.
13. Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA. 2005; 102: 18544-9.
14. Quartuccio L, Fabris M, Salvin S, et al. Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. Rheumatology (Oxford). 2007; 46: 1657-61.
15. Sansonno D, Lauletta G, Nisi L, et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol. 2003; 133: 275-82.
16. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005; 227-36.
17. Trejo O, Ramos-Casals M, García-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001; 80: 252-62.
18. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004; 33: 355-74.
19. Terrier B, Karras A, Cluzel P, et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol. 2013; 11: 265-72.
20. Vermeersch P, Gijbels K, Mariën G, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008; 54: 39-43.
21. Müller RB, Vogt B, Winkler S, et al. Detection of low level cryoglobulins by flow cytometry. Cytometry A. 2012; 81: 883-7.
22. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011; 70: 1183-90.
23. Ramos-Casals M, Robles A, Brito-Zerón P et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum. 2006; 36: 189-96.
24. Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013 Aug 22. [Epub ahead of print].
25. Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis. 2013 Aug 6. [Epub ahead of print].
26. Piluso A, Giannini C, Fognani E, et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat. 2013; 20: 107-14.
27. Vujosevic S, Tempesta D, Noventa F, et al. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology. 2012; 56: 455-63.
28. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus-associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print].
29. De Vita S. Treatment of mixed cryoglobulinemia: a rheumatology perspective. Clin Exp Rheumatol. 2011; 29: S99-103.
30. Ferri C, Sebastiani M, Antonelli A, et al. Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther. 2012; 14: 215.
31. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010; 116: 326-34.
32. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010; 116: 343-53.
33. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010; 116: 335-42.
34. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012; 64: 835-42.
35. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012; 64: 843-53.
36. Sène D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009; 60: 3848-55.
37. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012; 119: 5996-6004.
38. Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013; 72: 374-80.
39. Tzioufas AG, Boumba DS, Skopouli FN, et al. Mixed monoclonal cryoglobulinemia and monoclonal RF cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum. 1996; 39: 767-72.
40. Brito-Zerón P, Ramos-Casals M, Bové A, et al. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007; 46: 1359-62.
41. Trejo O, Ramos-Casals M, López-Guillermo A, et al. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases. Semin Arthritis Rheum. 2003; 33: 19-28.
42. Quartuccio L, Isola M, Corazza L, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol. 2012; 30: S48-52.
43. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010; 62: 1787-1795.
44. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368: 1907-17.
45. Lake-Bakaar G, Jacobson I, Talal A. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol. 2012; 170: 231-7.
46. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011; 365: 2067-77.
47. Howell J, Angus P, Gow P, et al. Toll-like receptors in hepatitis C infection: implications for pathogenesis and treatment. J Gastroenterol Hepatol. 2013; 28: 766-76.
48. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013: 369: 1035-45.
49. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994; 330: 751-6.
50. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994; 84: 3336-43.
51. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood. 1997; 90: 3865-73.
52. Cresta P, Musset L, Cacoub P, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut. 1999; 45: 122-8.
53. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002; 46: 3317-26.
54. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003; 101: 3827-34.
55. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003; 101: 3818-26.
56. Saadoun D, Resche-Rigon M, Sene D, et al. RItuximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008; 67: 1431-6.
57. Terrier B, Saadoun D, Sène D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term follow up study of thirty-two patients. Arthritis Rheum. 2009; 60: 2531-40.
58. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010; 116: 343-53.
59. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virusrelated mixed cryoglobulinemia and severe liver disease. Blood. 2010; 116: 335-42.
60. Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011; 11: 48-55.
61. Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011; 10: 714-19.
62. Saadoun D, De Chambrun MP, Hermine O, et al. Rituximab plus fludarabine and cyclophosphamide is an effective treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken). 2013; 65: 643-7.